Clinical Trials Browser

INDUSTRY × balstilimab × Gastrointestinal × Clear all

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT06589440 2026-01-15

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Phase 2 Recruiting

70 enrolled

Gastrointestinal

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT05205330 2025-10-29

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Phase 1/2 Active not recruiting

107 enrolled

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT05608044 2025-09-04

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Phase 2 Active not recruiting

234 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Phase 1/2 Recruiting

71 enrolled

GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06751524 2024-12-30

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Available

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Clinical Trials

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval